Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO7171009 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| RO7171009: SAD | EXPERIMENTAL | Patients will receive a single dose of RO7171009, in multiple escalating cohorts. |
| RO7171009: MD | EXPERIMENTAL | Patients will receive RO7171009 at maximum tolerated dose (MTD), identified during the SAD stage for three doses. |
| Name | Type | Description |
|---|---|---|
| RO7171009 | DRUG | Patients will receive RO7171009 via ITV injection. |
Inclusion Criteria: * Participants aged greater than or equal to (\>/=) 50 years * Well demarcated area(s) of GA secondary to AMD with no evidence of prior or active choroidal neovascularization (CNV) in study eye Exclusion Criteria: Ocular Exclusion Criteria, Study Eye: * History of vitrectomy ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | REGN | 2 | PHASE3 | Pozelimab, Cemdisiran |
| Annexon, Inc. | ANNX | 1 | PHASE3 | Vonaprument |
| Belite Bio, Inc. ADR | BLTE | 1 | PHASE3 | Tinlarebant |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-81201887 |
| AbbVie, Inc. | ABBV | 1 | PHASE1 | ABBV-6628, SYFOVRE |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE1 | SAR446597, Sham Comparator |
| Ocugen Inc | OCGN | 1 | PHASE1 | OCU410 |
| Apellis Pharmaceuticals, Inc. | APLS | 1 | - | Pegcetacoplan |
RO7171009 is an investigational small molecule being studied for the treatment of geographic atrophy, a form of age-related macular degeneration. It is being developed by Roche Holding AG and is currently in Phase 1 clinical development.
The specific molecular target of RO7171009 has not been disclosed. It is a small molecule being investigated for its potential to treat geographic atrophy, a condition that causes progressive vision loss.
RO7171009 is being developed by Roche Holding AG, a pharmaceutical company traded on the OTC market under the ticker symbol RHHBY. The drug is currently in Phase 1 clinical development for geographic atrophy.
RO7171009 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 study has been completed to evaluate its safety and tolerability.
RO7171009 has one completed Phase 1 clinical trial, identified as NCT03295877. This study evaluated the safety and tolerability of RO7171009 in participants with geographic atrophy secondary to age-related macular degeneration. The trial enrolled 28 participants in the United States.